COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine - Yahoo Finance

Submitted by Anonymous (not verified) on Thu, 11/03/2022 - 10:00

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine Yahoo Finance

Log in to post comments